A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Clinical trial NCT06172322 · UNKNOWN
Trial details
- NCT number
- NCT06172322
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-28
- Primary completion
- 2025-04-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.